Neuroprotective effect of ibuprofen by intranasal application of mucoadhesive nanoemulsion in MPTP induced Parkinson model

다국어 초록 (Multilingual Abstract)

This study was to investigate the neuroprotective effect of Ibuprofen by intranasal route against inflammationmediated by dopaminergic neurodegeneration in 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice model of Parkinson’s disease (PD). Ibuprofen loaded sodium hyaluronate based mucoadhesive nanoemulsion (MNEI) was developed by using response surface methodology (RSM) and was characterized. Male C57BL/6 mice were first treated with four intraperitoneal injections of MPTP (20 mg/kg of body weight) at 2 h intervals followed by Ibuprofen for 2 consecutive weeks at 2.86 mg/kg of body weight per day.
Optimal MNEI containing 3 % Labrafil M 1944 CS as oil phase, 36 %of Accenon CC and Transcutol P at 3:1 ratio and 0.5 % sodium hyaluronate was stable, non-ciliotoxic with 46.3 ± 2.28 nm as average globule size PdI value and TEM result showed the narrow size distribution of MNEI. The result showed that all three independent variables had a significant effect (p\0.05) on the responses. In-vivo results revealed significant reduction of MPTP-mediated dopamine depletion after nasal administration of Ibuprofen through MNEI. MPTP intoxication significantly decreased striatal DA content to 29.92 % which was elevated to 58.21 % after Ibuprofen treatment using MNEI. Significant improvement in motor performance and gross behavioural activity of the mice was observed through the findings of rota-rod and open field test findings. Findings of the investigation revealed that Ibuprofen through developed MNEI was shown to protect neurons against MPTP-induced injury in the striatum and could be a promising approach to treat PD.

참고문헌 (Reference)

1 Ben SY., "Using monoamine oxidase type B inhibitors in Parkinson’s disease" 329 : 581-582, 2004

2 Liu GP., "Tyrosine hydroxylase as a target for deltamethrin in the nigrostriatal dopaminergic pathway" 19 : 27-34, 2006

3 Aid S., "Targeting cyclooxygenases-1 and-2 in neuroinflammation : therapeutic implications" 93 : 46-51, 2011

4 Pathak R., "Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route" 4 : 151-160, 2014

5 Chopra S., "Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design" 67 : 120-131, 2007

6 Bassani TB., "Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats" 1593 : 95-105, 2014

7 Yang JL., "Neuroprotection effects of retained acupuncture in neurotoxin-induced Parkinson’s disease mice" 25 : 1452-1459, 2011

8 Cardoso SM., "Neurodegenerative pathways in Parkinson’s disease : therapeutic strategies" 4 : 405-419, 2005

9 Bittera C., "Nasal drug delivery in humans" 40 : 20-35, 2011

10 Hussein O., "Nanoemulsion as a potential ophthalmic delivery system" 10 : 808-819, 2009

11 Ali S., "NSAID use and the risk of Parkinson’s disease" 26 : 769-779, 2009

12 Ved PM., "Mucoadhesive strength Poly(ethelene oxide/propelene oxide)copolymer thermoreversible gelling system for the enhancement of intranasal zidovudine to the brain" 411 : 1-9, 2011

13 Hsieh YC., "MPP+-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress" 384 : 157-167, 2011

14 Kumar M., "Intranasal nanoemulsion based brain targeting drug delivery system of risperidone" 24 : 285-291, 2008

15 Elshafeey AH., "Intranasal microemulsion of sildenafil citrate : in vitro evaluation and in vivo pharmacokinetic study in rabbits" 10 : 361-367, 2009

16 Leah RH., "Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease" 9 : S5-S11, 2009

17 Scott GS., "Improving the in vitro prediction of in vivo central nervous system penetration : integrating permeability, p-glycoprotein efflux, and free fractions in blood and brain" 316 : 1282-1289, 2005

18 Gannu AR., "Formulation optimization and evaluation of microemulsion based transdermal therapeutic system for nitrendipine" 33 : 223-233, 2012

19 Patel BM., "Formulation and kinetic modeling of curcumin loaded intranasal mucoadhesive microemulsion" 4 : 81-83, 2012

20 Gannu R., "Enhanced bioavailability of lacidipine via microemulsion based transdermal gels : formulation optimization, ex vivo and in vivo characterization" 388 : 231-241, 2010

21 Harris AS., "Effect of viscosity on particle size, deposition, and clearance of nasal delivery systems containing desmopressin" 77 : 405-408, 1988

22 Hapse SA., "Difference spectrophotometric estimation and validation of ibuprofen from bulk and tablet dosage form" 3 : 18-23, 2011

23 Shafiq S., "Development and bioavailability assessment of ramipril nanoemulsion formulation" 66 : 227-243, 2007

24 Mandal S., "Design and development of carbamazepine mucoadhesive Microemulsion for intranasal delivery : an ex vivo study" 3 : 56-60, 2010

25 Khan S., "Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats" 61 : 669-675, 2009

26 Choudhary S., "Bioanalytical method development and validation of ibuprofen using RP–HPLC" 2 (2): 312-321, 2012

27 Joakim EC., "Barriers in the developing brain and neurotoxicology" 33 (33): 586-604, 2012

28 Barbiero JK., "Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson’s disease" 216 : 186-192, 2011

29 Michele BD., "A sensitive and reliable locomotor rating scale for open field testing in rats" 12 : 21-26, 1995

30 Hiromi S., "A rotarod test for evaluation of motor skill learning" 189 : 180-185, 2010